Study of Abemaciclib in Dedifferentiated Liposarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Dedifferentiated Liposarcoma
- Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02846987
- Collaborators
- Eli Lilly and Company
- Investigators
- Principal Investigator: Mark Dickson, MD Memorial Sloan Kettering Cancer Center
Get Well Soon